Blood & Bone Marrow Cancer Screening


What is Myeloid Cancer?

Myeloid leukemias are a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cells. Symptoms may include feeling tired, shortness of breath, easy bruising and bleeding, and increased risk of infection. Occasionally, spread may occur to the brain, skin, or gums. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.


Risk factors include smoking, previous chemotherapy or radiation therapy, myelodysplastic syndrome, and exposure to the chemical benzene. The underlying mechanism involves replacement of normal bone marrow with leukemia cells, which results in a drop in red blood cells, platelets, and normal white blood cells. Diagnosis is generally based on bone marrow aspiration and specific blood tests. AML has several subtypes for which treatments and outcomes may vary.

AML typically is initially treated with chemotherapy, with the aim of inducing remission. People may then go on to receive additional chemotherapy, radiation therapy, or a stem cell transplant. The specific genetic mutations present within the cancer cells may guide therapy, as well as determine how long that person is likely to survive. Arsenic trioxide may be tried in cases that have recurred following usual treatments

What is the Oncomine Myeloid Assay?

The Oncomine Myeloid Research Assay enables you to interrogate all relevant DNA mutations and fusion transcripts associated with myeloid disorders in a single NGS run. The targeted genes include those with published relevance to provide a research focused intent and a comprehensive way of investigating the genomic features associated with hematological malignancies.

The Ion Torrent Oncomine Myeloid Research Assay is a comprehensive, targeted NGS assay designed to assist in the understanding of myeloid cancer. Specifically, it interrogates relevant DNA mutations and fusion transcripts associated with myeloid disorders in a quick and easy NGS run. Our panel is comprised of 40 key DNA target genes and 29 driver genes in a broad fusion panel to cover all the major myeloid disorders: acute myeloid leukemia (AML), myeloid dysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML)

Strategic Gene targets

The content of our panel was carefully selected by a dedicated team of manual curators together with extensive consultation with global experts and international guidelines.



Our work flow is based on massive parallel sequencing(Next Generation Sequencing) of DNA. We use automated DNA extraction, Library Preparation(of DNA & RNA) and Template preparation for the sequencing process. On Sequencing we use high-throughput sequencing either Ion S5 or Ion PGM Systems. Upon receiving the genetic variants we further pass the data through an automated cancer knowledge base called Oncomine to pair them with relevant clinical data to form a report.


Benefits of Early Myeloid Cancer Screening

  • 1. Ease of use​​—one simple, robust workflow with all mutations encapsulated in two DNA and one RNA pool.
  • 2. Effective designs​​—great coverage of challenging targets such as CEBPA and internal tandem duplications of FLT3 (FLT3-ITDs).
  • 3. Flexibility​​—verified with blood and bone marrow samples.
  • 4. Speed​​—from samples to answers in <3 days